Business Context and Reporting Period
This Form 8-K is a current report filed by Churchill Capital Corp X (the "Registrant") on November 4, 2025. The filing reports on the progress of a proposed business combination with ColdQuanta, Inc. (the "Company"), a Delaware corporation focused on quantum computing technologies. The Registrant is an emerging growth company incorporated in Delaware.
Key Financial Metrics
This filing is a current report regarding a corporate event and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics for either Churchill Capital Corp X or ColdQuanta, Inc. for the reporting period.
Material Changes and Transaction Status
- Merger Agreement: As previously disclosed on September 8, 2025, Churchill and ColdQuanta entered into an Agreement and Plan of Merger and Reorganization.
- SEC Filing: On October 29, 2025, the parties confidentially submitted a draft registration statement on Form S-4 to the SEC.
- Shareholder Vote: The proposed transaction is subject to approval by Churchill's shareholders. A definitive proxy statement/prospectus will be distributed once the Form S-4 is declared effective.
- Trading Symbols: Churchill's securities trade on The Nasdaq Stock Market LLC under symbols CCCXU (Units), CCCX (Class A ordinary shares), and CCCXW (Warrants).
Guidance, Outlook, and Risks
The filing includes extensive forward-looking statements regarding the potential benefits of the transaction, market opportunity, and commercialization timelines. Management explicitly disclaims any obligation to update these statements.
Key Risks Disclosed
- Commercialization: ColdQuanta is pursuing emerging technology and faces significant technical challenges; market acceptance is not guaranteed.
- Financial History: ColdQuanta has a history of net losses and limited operating history.
- Redemption Risk: If Churchill shareholders elect to redeem their shares, the combined company may lack sufficient cash to execute its business plans.
- Regulatory and Transaction Risk: Delays or failure to obtain required regulatory approvals could terminate the agreement or adversely affect the combined company.
- Revenue Concentration: ColdQuanta relies heavily on contracts with government or state-funded entities.
Investor Verification Checklist
- Verify the status of the Form S-4 registration statement and the expected timeline for the definitive proxy statement/prospectus.
- Review the redemption rights available to Churchill shareholders and the potential impact on the combined company's liquidity.
- Examine ColdQuanta's historical financial performance and capital requirements in upcoming filings, as this 8-K does not provide specific financial data.
- Assess the regulatory approval requirements for the merger and any potential delays.
- Confirm the warrant exercise price of $11.50 per share and the terms of the securities to be issued to ColdQuanta stockholders.